Prevalence and predictors of cannabis use among men receiving androgen-deprivation therapy for advanced prostate cancer

Ahmad Mousa, MD1,2; Michele Petrovic, BSc2; Neil E. Fleshner, MD, MPH, FRCSC1,2

1University of Toronto, Faculty of Medicine, Toronto, ON, Canada; 2Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada

Cite as: Can Urol Assoc J 2020;14(1):E20-6. http://dx.doi.org/10.5489/cuaj.5911

Published online June 17, 2019

Abstract

Introduction: Prostate cancer patients receiving androgen-deprivation therapy (ADT) often experience a combination of disease symptoms and treatment side effects. The therapeutic use of cannabis to alleviate these side effects has not been studied, despite increasing patient interest. With the increasing availability of cannabis, it is important for clinicians to understand the prevalence, predictors, and perceived benefits of cannabis use among patients with prostate cancer.

Methods: A total of 222 men undergoing ADT were assessed in this two-part study. In part one, the cannabis-use questionnaire was administered to 56 men, probing demographics, usage habits, perspectives, and degrees of symptom relief related to cannabis use. In part two, 191 cryopreserved urine samples were retrieved and analyzed for the presence of tetrahydrocannabinol (THC) metabolite 11-nor-Δ9-THC-COOH. The respondents were then stratified into two groups, users vs. non-users, and statistical analyses were conducted.

Results: Questionnaire data revealed that 23.2% of surveyed men had recently used cannabis. In contrast, 5.8% of men had detectable levels of THC metabolite in their urine. Combined questionnaire and urine data revealed that cannabis users were significantly younger (p=0.003) and had lower testosterone levels (p=0.003) than non-users. The majority of men experiencing common ADT side effects reported some degree of relief following cannabis use.

Conclusions: Cannabis use among men with advanced prostate cancer receiving ADT is more prevalent than in the general population and the majority of other oncological cohorts. Lower testosterone levels and reported therapeutic benefit among cannabis users warrants confirmation in appropriate clinical trials.

Introduction

Cannabis use by humans has been documented since ancient history. Despite its classification as a controlled substance in many countries, cannabis (most commonly Cannabis sativa) has recently made strides towards decriminalization and acceptance by mainstream society. In 2001, cannabis was legalized for medical use in Canada following recommendations by Health Canada. A United Nations study estimated that 12.6% of Canadian adults have used cannabis in the past year, which is a remarkably higher rate than the global average of 2.8–4.5%. Of particular interest, the use of cannabis has increased by over 1.5% in adults aged 45 or older since 2002. Recent international moves towards decriminalization of cannabis have resulted in an increase in public interest for both its recreational and medical uses. Physician interest and approval for cannabis use has been well-documented in several studies, most recently in 2013, when a poll of 1446 physicians revealed that 76% approved of medical marijuana use.

Several studies have shown that C. sativa exhibits some efficacy in relieving nausea and vomiting, loss of appetite, and neuropathic pain. The use of cannabis has also been associated with several non-serious adverse events. One study has found that males who had ever smoked cannabis or those who were current cannabis smokers had a higher risk of prostate cancer than those with no history of its use. Reported acute adverse effects of cannabis include impaired episodic memory and learning, anxiety and panic attacks, perceptual alterations, and acute psychomotor retardation. Chronic adverse effects include addiction, chronic bronchitis, and carcinogenicity (if inhaled).

Prostate cancer patients receiving androgen-deprivation therapy (ADT) often experience a combination of disease symptoms and treatment side effects, including pain, fatigue, insomnia, hot flushes, irritability, depression, headache, nausea, and vomiting. To our knowledge, there are no published peer-reviewed studies to date that evaluate the prevalence of and/or attitudes of prostate cancer patients towards cannabis use. With the increasing availability and prevalence of cannabis use in the general population, particularly within the age groups experiencing the greatest burden of this disease, it is important that clinicians understand how many of their patients use cannabis and what their attitudes...
Methods

This was a two-part study involving 222 men with histologically confirmed invasive prostate cancer receiving ADT at the time of the study. Patient health information, including demographics, disease history, and laboratory values, were extracted from medical records and stored separately from other collected data. Blood samples for testosterone levels were collected and analyzed according to institutional guidelines at the University Health Network, Toronto Canada. Samples were analyzed using an Abbott Architect i2000 immunoassay, with a functional sensitivity allowing for titres to be reported as low as 0.2 nmol/L. Participants with testosterone levels analyzed at external labs were not included in this study.

In part one of the study, a five-page questionnaire was developed consisting of 18 multiple-choice questions probing the demographics (n=6), cannabis usage habits and perspectives (n=11), and degrees of symptom relief related to cannabis use (n=1). The questionnaire was approved by the institutional research ethics board at the University Health Network (UHN) in Toronto, Canada. The questionnaire has obvious content validity (Appendix 1; available at cuaj.ca). The questionnaire was administered to 56 men with histologically confirmed invasive prostate cancer currently receiving ADT in the outpatient clinic setting at Princess Margaret Cancer Centre in Toronto, Canada. Consent was obtained from patients in clinic and the questionnaire was completed using pen and paper on the same clinical day with research staff available to aid in completion. The questionnaire took approximately 20 minutes to complete. Data were gathered from patients between June and September of 2017. No payment was provided to study participants for their participation. Participants were assigned a study-specific numeric identifier and the collected data was de-identified and entered into a password-protected database.

In part two of the study, 191 cryopreserved urine supernatant samples were obtained from the Genitourinary (gU) BioBank at the University Health Network, Toronto, Canada. The gU BioBank is a research ethics board-approved investigator-initiated biobanking program that collects and archives biological specimens and data obtained from consenting urologic oncology patients. Patients providing consent to participate in the gU BioBank had urine specimens procured after the initiation of ADT for hormone-sensitive disease. Note the cryopreserved urine specimens were not necessarily from the same sample of survey respondents; overlap was moderate (n=25). The samples were subject to a single freezer-thaw cycle and analyzed at the Toxicology Laboratory at The Hospital for Sick Children, Toronto, Canada. Samples were analyzed using an Abbott Architect ci4100 immunoassay (Abbott, IL, U.S.), as per manufacturer’s instructions. This analysis detects the presence of the tetrahydrocannabinol (THC) metabolite 11-nor-delta-9-tetrahydrocannabinol (11-nor-Δ9-THC-COOH). A positive result indicates the presence of the metabolite at a concentration greater than 50 ng/mL, in concordance with cannabis testing guidelines established by the National Institute on Drug Abuse (NIDA), Department of Health and Human Services (DHHS), and the Substance Abuse and Mental Health Service Agency (SAMSHA).

Statistical analysis

The respondents were then stratified into two groups, users vs. non-users, and statistical analyses were conducted. For comparisons where combined questionnaire and urine data were analyzed, overlapping participants were stratified according to their self-reported questionnaire responses given the limited sensitivity of the urine assay, as outlined in our Discussion. The data were analyzed using IBM SPSS Statistics version 25 (IVM Corp, Armonk, NY). Missing values analysis revealed that no questionnaires had missing responses. Lilliefors tests were conducted to establish normality of the data. Continuous data were analyzed using Student t and Mann-Whitney U tests. Categorical data were analyzed using Pearson Chi-square tests.

Results

Subject characteristics

There was a total of 56 survey respondents. Approximately 2% of approached patients declined to participate. Demographics and characteristics are described in Tables 1 and 2A. Approximately 75% of the patients were 61 years of age or older (range 51–93). The mean age of survey respondents was 70 years. Although the survey population represented over nine ethnicities, about half of the patients were ethnically European (57%). Approximately a quarter of the survey respondents had education less than post-secondary education (27%).

Cryopreserved urine samples were analyzed from a total of 191 patients. Approximately 79% of the patients were 61 years of age or older (range 50–94). The mean age of patients at the time of urine sample collection was 70 years. Characteristics are described in Table 2B. No other demographic data were collected from patients providing urine samples.
Primary outcome

Questionnaire data revealed that 23.2% (13/56) of surveyed men undergoing ADT had used cannabis within the past six months. In contrast, 5.8% (11/191) of analyzed urine samples tested positive for the presence of THC metabolite.

Secondary outcomes

Combined questionnaire and urine data (Table 3) revealed that cannabis users (n=22) tend to be significantly younger (mean age 64.36 vs. 71.48 years; p=0.003) and have lower testosterone levels (mean T level 0.48 vs. 0.85 nmol/L; p=0.003) compared to non-users (n=200). When controlled for age, analyses also revealed that users were on ADT for significantly less time than non-users (mean time on ADT 2.19 vs. 3.28 years; p=0.011).

Questionnaire data revealed that the most widely used method of cannabis consumption was in oils/tinctures (62%), followed closely by smoking/vaporization (54%). Patterns and habits of consumption in the surveyed patients are summarized in Table 4. The most common reasons for cannabis use (Fig. 1) were pain (46%), low energy (46%), hot flushes (23%), and irritability/mood (23%). With the exception of hot flushes, the majority of men reported some degree of relief from all noted ADT side effects following the use of cannabis (Fig. 2). Notably, 31% (4/13) of users stated that they believed cannabis could be used to directly treat cancer. Approximately 70% (9/13) of users reported experiencing at least one of the side effects of cannabis use (Fig. 3). The most commonly reported side effects were increased appetite, memory loss, and cough.

Table 1. Demographics of questionnaire respondents by usage status

| Variable                  | Non-users (n=43 (77%)) | Users (n=13 (23%)) | p     |
|---------------------------|------------------------|--------------------|-------|
| Age (years)               |                        |                    |       |
| 50–60                     | 8 (17)                 | 6 (46)             |       |
| 61–70                     | 11 (26)                | 3 (23)             |       |
| 71–80                     | 10 (23)                | 2 (15)             |       |
| 81–90                     | 12 (28)                | 2 (15)             |       |
| 91+                       | 2 (5)                  | 0 (0)              |       |
| Marital Status            |                        |                    | 0.817 |
| Single                    | 6 (14)                 | 3 (23)             |       |
| Married                   | 30 (70)                | 8 (62)             |       |
| Separated/divorced        | 5 (12)                 | 1 (8)              |       |
| Widowed                   | 2 (5)                  | 1 (8)              |       |
| Ethnicity                 |                        |                    | 0.864 |
| Afro-Caribbean            | 4 (9)                  | 2 (15)             |       |
| Arab                      | 2 (5)                  | 1 (8)              |       |
| Central/South African     | 1 (2)                  | 0 (0)              |       |
| East Asian                | 3 (7)                  | 0 (0)              |       |
| Eastern European          | 7 (16)                 | 4 (31)             |       |
| Indian Subcontinent       | 3 (7)                  | 0 (0)              |       |
| Latin                     | 2 (5)                  | 0 (0)              |       |
| South Pacific/Oceania     | 1 (2)                  | 0 (0)              |       |
| Western European          | 16 (37)                | 5 (38)             |       |
| Other                     | 4 (9)                  | 1 (8)              |       |
| Education                 |                        |                    | 0.476 |
| Less than high school     | 2 (5)                  | 2 (15)             |       |
| High school               | 8 (19)                 | 3 (23)             |       |
| College                   | 12 (28)                | 3 (23)             |       |
| University                | 10 (23)                | 4 (31)             |       |
| Postgraduate              | 11 (26)                | 1 (8)              |       |
| Employment                |                        |                    | 0.047 |
| Full time                 | 8 (19)                 | 7 (54)             |       |
| Part time                 | 2 (5)                  | 2 (15)             |       |
| Retired due to disability | 5 (11)                 | 1 (8)              |       |
| Retired due to age        | 27 (62)                | 3 (23)             |       |
| Unemployed                | 1 (2)                  | 0 (0)              |       |
| Annual income (CAD)       |                        |                    | 0.866 |
| Less than $25 000         | 6 (14)                 | 1 (8)              |       |
| $25 000–49 999            | 9 (21)                 | 2 (15)             |       |
| $50 000–75 000            | 4 (9)                  | 2 (15)             |       |
| More than $75 000         | 15 (35)                | 4 (31)             |       |
| Prefer not to answer      | 9 (21)                 | 4 (31)             |       |

Table 2A. Characteristics of questionnaire respondents by usage status

| Variable                  | Non-users (n=43 (77%)) Mean (SD) | Users (n=13 (23%)) Mean (SD) | p     |
|---------------------------|-----------------------------------|-------------------------------|-------|
| Age (years)               | 72 (10.63)                        | 65 (10.85)                    | 0.043 |
| Years on ADT              | 3.83 (3.61)                       | 1.71 (1.50)                   | 0.029 |
| Type of ADT               |                                    |                               | 0.482 |
| Eligard (Leuprolide)      | 9 (21%)                           | 5 (38%)                       |       |
| Firmagon (Degarelix)      | 0                                 | 0                             |       |
| Lupron (Leuprolide)       | 17 (40%)                          | 6 (46%)                       |       |
| Trelstar (Triptorelin)    | 4 (9%)                            | 0                             |       |
| Zoladex (Goserelin)       | 12 (28%)                          | 2 (15%)                       |       |
| Casodex (Biclutamide)     | 1 (2%)                            | 0                             |       |
| Most recent testosterone level (nmol/L) | 1.03 (1.68) | 0.53 (0.51) | 0.108 |

Table 2B. Characteristics of urine data participants by usage status

| Variable                  | Non-users (n=180 (94%)) Mean (SD) | Users (n=11 (6%)) Mean (SD) | p     |
|---------------------------|-----------------------------------|-------------------------------|-------|
| Age (years)               | 70.55 (10.24)                     | 63.55 (8.03)                  | 0.023 |
| Years on ADT              | 3.00 (2.91)                       | 2.59 (4.11)                   | 0.046 |
| Type of ADT               |                                    |                               | 0.856 |
| Eligard (Leuprolide)      | 27 (15%)                          | 3 (27%)                       |       |
| Firmagon (Degarelix)      | 10 (6%)                           | 0                             |       |
| Lupron (Leuprolide)       | 69 (38%)                          | 3 (27%)                       |       |
| Suprefact (Buserelin)     | 2 (1%)                            | 0                             |       |
| Trelstar (Triptorelin)    | 9 (5%)                            | 1 (9%)                        |       |
| Zoladex (Goserelin)       | 60 (33%)                          | 4 (36%)                       |       |
| Casodex (Biclutamide)     | 3 (2%)                            | 0                             |       |
| Most recent testosterone level (nmol/L) | 0.86 (1.34) | 0.41 (0.24) | 0.016 |

ADT: androgen-deprivation therapy; SD: standard deviation.
Among non-users, 79% (34/43) expressed the belief that cannabis has at least one perceived benefit (Table 5). The most commonly perceived benefits of cannabis use among non-users were relief from pain, depression, and irritability. Among the surveyed non-users, 28% (12/43) stated that they believed cannabis could be used to directly treat cancer.

The self-reported use of cannabis in prostate cancer patients is greater than the majority of other oncological cohorts (Fig. 4).

**Discussion**

This two-part study of prostate cancer patients at a large cancer center located in a region with cannabis legalized for medical use only at the time of the study found that nearly a quarter of surveyed patients with prostate cancer on ADT reported current or recent cannabis use. In contrast with the survey data, approximately 6% of urine samples from men meeting the same inclusion criteria were found to contain THC metabolites. This discrepancy can largely be attributed to the limitations of the assay and the pharmacokinetics of THC and non-THC cannabinoid constituents. The assay used in this study detected the presence of THC metabolite 11-nor-Δ9-THC-COOH. THC content varies significantly and is not a significant component of a number of prescription and non-recreational cannabis products, such as the oils and tinctures, which were used by a majority of study respondents. Furthermore, in respondents using cannabis products containing THC, urine metabolites can become undetectable as early as seven days following last use. Rate of THC metabolism depends on several factors, including age, metabolism, usage frequency, dosage, and body habitus. The discrepancy between survey and urine data, therefore, reflects the need for the development of accurate and simple assays that extend the spectrum of readily available cannabis screening tests beyond THC metabolites. Furthermore, this discrepancy highlights the heterogenous, unregulated nature of cannabis products — a significant barrier in the non-controlled study of cannabis use.

A literature search revealed that although there was an abundance of peer-reviewed studies exploring the associations between cannabis use and cancer incidence, there were only a total of eight studies evaluating the prevalence of cannabis use among oncological cohorts. When compared to the reported rates in the majority of these other oncological cohorts, the prevalence of cannabis use in prostate cancer patients on ADT is greater. Despite an abundance of data, these comparisons are limited by the fact that most studies reporting cannabis usage rates are single-center studies confounded by site-specific legal, cultural, and geographical factors.

One surprising observation from our study is that compared to non-users, cannabis users had significantly lower testosterone levels. Analyses

![Fig. 1. Reasons for cannabis use among survey respondents. The reasons for user were not mutually exclusive responses.](image-url)
also revealed that when the data was controlled for age, cannabis users were on ADT for a significantly shorter period of time compared to non-users. Given our finding that cannabis users tend to be younger than non-users, it is difficult to hypothesize that poor Leydig cell reserve is the cause of lower testosterone levels. Previous research in men has demonstrated depression of plasma testosterone levels after both acute and chronic cannabis use.\textsuperscript{22,23} Further research is required to determine if cannabis use can further lower testosterone levels among men on ADT, particularly in light of novel data suggesting that among men on ADT, lower testosterone levels are associated with improved outcomes.\textsuperscript{24,25}

The majority of survey respondents denied any current or recent use of cannabis. Interestingly, 79% of non-users held a belief that cannabis may help treat at least one of the common symptoms and side effects associated with prostate cancer and ADT. These findings demonstrate the interest and optimism of prostate cancer patients towards potential therapeutic uses of cannabis. Interestingly, the same proportion of users (31%) and non-users (28%) believed that cannabis may be used to treat their prostate cancer. The notion that cannabis may have a curative role in cancer management is one that is prevalent among many members of the public and is a popular discussion topic on internet forums around the world.\textsuperscript{26,27} despite the absence of any clinical trials to support its use in the primary treatment of malignancies. These findings highlight the need for clinicians to seek appropriate education on the topic in order to engage in effective dialogue with their patients.

It is important to note that the majority men in this study who consumed cannabis reported experiencing at least one side effect. The reported effects were short-term and included hallucinations, cough, memory loss, and increased appetite. Due to the study design, long-term side effects of cannabis use were not evaluated. There remains a significant gap in the literature on the evaluation of long-term effects of cannabis; most available data is based on in vitro or preclinical studies, severely outdated, or based on inadequately designed trials with small sample sizes.

We acknowledge a number of limitations of our investigation. Our study was conducted at a single center within a geographical region where cannabis was a controlled substance at the time of the study, only available for legal use in a narrow spectrum of indications requiring physician prescription, leading to a combined selection/geographical bias. This selection bias may affect generalizability to other populations. Furthermore, we rec-

![Reported relief from androgen-deprivation therapy side effects following cannabis use.](image)

**Table 4. Patterns of consumption in cannabis users**

| Variable | n (%) |
|----------|-------|
| Number of years that subjects have consumed cannabis | |
| Less than 1 year | 4 (31) |
| 1–3 years | 2 (15) |
| 3–5 years | 0 (0) |
| Over 5 years | 7 (54) |
| Methods of cannabis consumption | |
| Smoking/vaporization | 7 (54) |
| Edibles (smoothies, candies, baked goods, etc.) | 2 (15) |
| Oils/tinctures | 8 (62) |
| Topical creams/patches | 0 (0) |
| Other | 0 (0) |
| Men using more than one method of consumption | 3 (23) |
| Number of days per week that cannabis is used | |
| 1–2 | 6 (46) |
| 3–4 | 2 (15) |
| 5–6 | 1 (8) |
| 7 (every day) | 4 (31) |
| Time of use | |
| Subjects who usually take cannabis just after waking up | 1 (8) |
| Subjects who usually take cannabis between 6 am and noon | 1 (8) |
| Subjects who usually take cannabis between noon and 6 pm | 6 (46) |
| Subjects who usually take cannabis just before going to bed | 4 (31) |
| Subjects who take cannabis whenever it is felt to be necessary | 1 (8) |
Cannabis use among men receiving ADT

Recognize that self-reported data collected via cross-sectional study has inherent limitations and biases. Measurement bias (under-reporting of use) is likely due to two factors: social stigma surrounding cannabis and the legal connotations of the access of cannabis products without a prescription.

Conclusions

Cannabis use among men with advanced prostate cancer receiving ADT is more prevalent than in the general population and the majority of other oncological cohorts. Testosterone levels appear lower among users and warrants further investigation. Both users and non-users appear to be open and optimistic towards the potential therapeutic benefits of cannabis and these effects should be proven in the context of appropriate clinical trials.

Competing interests: The authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

Table 5. Opinions on cannabis use in non-users

| Do you believe that cannabis may... | n (%) |
|-----------------------------------|-------|
| Treat cancer                      | 12 (28) |
| Prevent shrinkage of testicles    | 2 (5) |
| Increase appetite                 | 10 (23) |
| Relieve pain                      | 27 (63) |
| Relieve fatigue and/or low energy| 12 (28) |
| Relieve hot flushes               | 4 (9) |
| Relieve irritability and relax mood| 14 (33) |
| Relieve depression                | 15 (35) |
| Relieve headache                  | 8 (19) |
| Relieve nausea                    | 9 (21) |
| Relieve vomiting                  | 5 (12) |
| Be used for recreation and/or pleasure| 14 (33) |
| Has no benefits (i.e., responded to no to all)| 9 (21) |

References

1. Ducatti-Flister L. The economic case for marijuana legalization in Canada. *J Altern Perp Soc Sci* 2012;5:96-100.
2. Statistics Canada Census, q82-003x; 2012.
3. Adler JK, James AC. Medicinal use of marijuana – polling results. *N Engl J Med* 2013;368:866-8. https://doi.org/10.1056/NEJMba1300970
4. Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: Quantitative systematic review. *BMJ* 2001;323:16. https://doi.org/10.1136/bmj.323.7303.16
5. Cann K, Tim C. Cannabinoids and appetite: Food craving and food pleasure. *Int Rev Psychiatry* 2009;21:163-71. https://doi.org/10.1080/09540260902728210
6. Pahazò E, Luongo L, Navella V, et al. The role of cannabinoid receptors in the descending modulation of pain. *Pharmaceuticals (Basel)* 2010;3:2661-73. https://doi.org/10.3390/ph3082661
7. Sidney S, Queenerbery CP, Friedman GB, et al. Marijuana use and cancer incidence (California, United States). *Cancer Causes Control* 1997;8:7224. https://doi.org/10.1023/A:1018427320650
8. Curran HV, Brignell C, Fletcher S, et al. Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 2002;164:61-70. https://doi.org/10.1007/s00213-002-1169-0
9. Hall W, Nutt D. Adverse effects of cannabis. Lancet 1998;352:1611-6. https://doi.org/10.1016/S0140-6736(98)05021-1
10. Higano Celestia S. Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology 2003;61:32-8. https://doi.org/10.1016/S0090-4295(02)02397-X
11. Pitts JE, O’Neil PJ, Leggo KP. Survey variation in the THC content of illicitly imported cannabis products, 1984–1989. J Pharm Pharmacol 1990;42:817-20. https://doi.org/10.1111/j.2042-7158.1990.tb07032.x
12. Fattore L, Walter F. Beyond THC: The new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5:60. https://doi.org/10.3389/fnbeh.2011.00060
13. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannabinol, cannabidiol, and cannabinol. Cannabinoids Springer, Berlin, Heidelberg, 2005:657-90. https://doi.org/10.1007/3-540-26573-2_23
14. Pergam SA, Woodfield MC, Lee CM, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017;123:4488-97. https://doi.org/10.1002/cncr.30879
15. Aldington S, Harwood M, Cox B, et al. Cannabis use and risk of lung cancer: A case-control study. Eur Respir J 2008;31:280-6. https://doi.org/10.1183/09031936.00065707
16. Deling JR, Doody DR, Sun X, et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 2009;115:1215-23. https://doi.org/10.1002/cncr.24159
17. Zhang Z, Morgenstern H, Spitz MR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999;8:1071-8
18. Aldington S, Harwood M, Cox B, et al. Cannabis use and cancer of the head and neck: Case-control study. Otolaryngol Head Neck Surg 2008;138:574-80. https://doi.org/10.1016/j.ototins.2007.12.002
19. Berthiller J, Straul K, Bonial M, et al. Cannabis smoking and risk of lung cancer in men: A pooled analysis of three studies in Maghem. J Thorac Oncol 2008;3:1398-403. https://doi.org/10.1097/JTO.0b013e31816b6de
20. Thomas AA, Wellner LP, Quinn VP, et al. Association between cannabis use and the risk of bladder cancer: Results from the California Men’s Health Study. Urology 2015;85:388-93. https://doi.org/10.1016/j.urology.2014.08.060
21. Firth NA. Marijuana use and oral cancer: A review. Oral Oncol 1997;33:398-401. https://doi.org/10.1016/S0959-1819(97)00022-6
22. Kalodner RC, Masters WH, Kalodner MA, et al. Depression of plasma testosterone levels after chronic intensive marijuana use. N Engl J Med 1974;290:872-4. https://doi.org/10.1056/NEJM197401290160202
23. Kalodner RC, Lessin P, Tara G, et al. Depression of plasma testosterone with acute marijuana administration. Pharmacol Mono Drug 1976;217-25.
24. Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent vs. continuous ADT. J Clin Oncol 2015;33:1151. https://doi.org/10.1200/JCO.2014.58.2973
25. Klotz L, Shayan B, Guillemette C, et al. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement. Can Urol Assoc J 2018;12:30-37. https://doi.org/10.5489/cuaj.5116
26. Cancer Research UK. Discussion forum (online users): Friend is using cannabis oil as treatment? Feb. 3, 2017. Available at: www.cancerresearchuk.org/about-cancer/cancer-chat/thread/friend-is-using-cannabis-oil-as-treatment. Accessed June 17, 2019.
27. Steemit. Discussion forum (online users): Cannabis oil and cancer treatment suggestion forum May 1, 2016. Available at: steemit.com/journey/@ajwalkerart/cannabis-oil-and-cancer-treatment-suggestion-forum. Accessed June 17, 2019.

Correspondence: Dr. Ahmad Mousa, Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; ahmad.mousa@mail.utoronto.ca

Fig. 4. Self-reported prevalence of cannabis use (%) among oncological cohorts. GI: gastrointestinal.